Negative Regulation of NF-κB by the ING4 Tumor Suppressor in Breast Cancer

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Byron, Sara A ^a   Min, Elizabeth ^a   Thal, Tanya S ^a,b   Hostetter, Galen ^a,c   Watanabe, Aprill T ^a   Azorsa, David O ^a   Little, Tanya H ^a   Tapia, Coya ^a   Kim, Suwon ^a,b,d  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF GROWTH 4 PROTEIN; TRANSCRIPTION FACTOR RELA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GRADING; CELL INVASION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOWN-REGULATION; HOMEODOMAIN PROTEINS; HUMANS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84867137097     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046823     Document Type: Article

References (56)

1. Hayden MS, Ghosh S, (2008) Shared principles in NF-kappaB signaling. Cell 132: 344-362.
2. Vallabhapurapu S, Karin M, (2009) Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27: 693-733.
3. Ben-Neriah Y, Karin M, (2011) Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 12: 715-723.
4. Grivennikov SI, Greten FR, Karin M, (2010) Immunity, inflammation, and cancer. Cell 140: 883-899.
5. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB, (2011) NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene 30: 1615-1630.
6. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, et al. (2004) NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 101: 10137-10142.
7. Makino K, Day CP, Wang SC, Li YM, Hung MC, (2004) Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required for HER2/neu-induced NF-kappaB antiapoptotic pathway. Oncogene 23: 3883-3887.
8. Biswas DK, Iglehart JD, (2006) Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J Cell Physiol 209: 645-652.
9. Merkhofer EC, Cogswell P, Baldwin AS, (2010) Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha. Oncogene 29: 1238-1248.
10. Cao Y, Luo JL, Karin M, (2007) IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci U S A 104: 15852-15857.
11. Liu M, Ju X, Willmarth NE, Casimiro MC, Ojeifo J, et al. (2009) Nuclear factor-kappaB enhances ErbB2-induced mammary tumorigenesis and neoangiogenesis in vivo. Am J Pathol 174: 1910-1920.
12. Liu M, Sakamaki T, Casimiro MC, Willmarth NE, Quong AA, et al. (2010) The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res 70: 10464-10473.
13. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC, (2005) The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 12: S37-46.
14. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, et al. (2007) Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 7: 1-15.
15. Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD, et al. (2009) Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res 69: 8918-8925.
16. Pradhan M, Bembinster LA, Baumgarten SC, Frasor J, (2010) Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NF{kappa}B cooperativity at adjacent response elements. J Biol Chem 285: 31100-31106.
17. Shiseki M, Nagashima M, Pedeux RM, Kitahama-Shiseki M, Miura K, et al. (2003) p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res 63: 2373-2378.
18. Li X, Zhang Q, Cai L, Wang Y, Wang Q, et al. (2009) Inhibitor of growth 4 induces apoptosis in human lung adenocarcinoma cell line A549 via Bcl-2 family proteins and mitochondria apoptosis pathway. J Cancer Res Clin Oncol 135: 829-835.
19. Shen JC, Unoki M, Ythier D, Duperray A, Varticovski L, et al. (2007) Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res 67: 2552-2558.
20. Garkavtsev I, Kozin SV, Chernova O, Xu L, Winkler F, et al. (2004) The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428: 328-332.
21. Colla S, Tagliaferri S, Morandi F, Lunghi P, Donofrio G, et al. (2007) The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood 110: 4464-4475.
22. Li J, Li G, (2010) Cell cycle regulator ING4 is a suppressor of melanoma angiogenesis that is regulated by the metastasis suppressor BRMS1. Cancer Res 70: 10445-10453.
23. Kim S, Chin K, Gray JW, Bishop JM, (2004) A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer. Proc Natl Acad Sci U S A 101: 16251-16256.
24. Ozer A, Wu LC, Bruick RK, (2005) The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). Proc Natl Acad Sci U S A 102: 7481-7486.
25. Nozell S, Laver T, Moseley D, Nowoslawski L, De Vos M, et al. (2008) The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes. Mol Cell Biol 28: 6632-6645.
26. Tapia C, Zlobec I, Schneider S, Kilic E, Güth U, et al. (2011) Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer. Hum Pathol 42: 983-990.
27. Gunduz M, Nagatsuka H, Demircan K, Gunduz E, Cengiz B, et al. (2005) Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene 356: 109-117.
28. Li J, Martinka M, Li G, (2008) Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis 29: 1373-1379.
29. Fang F, Luo LB, Tao YM, Wu F, Yang LY, (2009) Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 18: 409-416.
30. Li M, Jin Y, Sun WJ, Yu Y, Bai J, et al. (2009) Reduced expression and novel splice variants of ING4 in human gastric adenocarcinoma. J Pathol 219: 87-95.
31. You Q, Wang XS, Fu SB, Jin XM, (2011) Downregulated Expression of Inhibitor of Growth 4 (ING4) in Advanced Colorectal Cancers: A Non-Randomized Experimental Study. Pathol Oncol Res 17: 473-477.
32. Wang QS, Li M, Zhang LY, Jin Y, Tong DD, et al. (2010) Down-regulation of ING4 is associated with initiation and progression of lung cancer. Histopathology 57: 271-281.
33. Coles AH, Gannon H, Cerny A, Kurt-Jones E, Jones SN, (2010) Inhibitor of growth-4 promotes IkappaB promoter activation to suppress NF-kappaB signaling and innate immunity. Proc Natl Acad Sci U S A 107: 11423-11428.
34. Kim S, Welm AL, Bishop JM, (2010) A Dominant Mutant Allele of the ING4 Tumor Suppressor Found in Human Cancer Cells Exacerbates MYC-Initiated Mouse Mammary Tumorigenesis. Cancer Res 70: 5155-5162.
35. Russell M, Berardi P, Gong W, Riabowol K, (2006) Grow-ING, Age-ING and Die-ING: ING proteins link cancer, senescence and apoptosis. Exp Cell Res 312: 951-961.
36. Aasland R, Gibson TJ, Stewart AF, (1995) The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biochem Sci 20: 56-59.
37. Palacios A, Muñoz IG, Pantoja-Uceda D, Marcaida MJ, Torres D, et al. (2008) Molecular basis of histone H3K4me3 recognition by ING4. J Biol Chem 283: 15956-15964.
38. Hung T, Binda O, Champagne KS, Kuo AJ, Johnson K, et al. (2009) ING4 mediates crosstalk between histone H3 K4 trimethylation and H3 acetylation to attenuate cellular transformation. Mol Cell 33: 248-256.
39. Doyon Y, Cayrou C, Ullah M, Landry AJ, Côté V, et al. (2006) ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell 21: 51-64.
40. Saksouk N, Avvakumov N, Champagne KS, Hung T, Doyon Y, et al. (2009) HBO1 HAT complexes target chromatin throughout gene coding regions via multiple PHD finger interactions with histone H3 tail. Mol Cell 33: 257-265.
41. Azorsa DO, Meltzer PS, (1999) Production and characterization of monoclonal antibodies to the steroid receptor coactivator AIB1. Hybridoma 18: 281-287.
42. Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, et al. (2007) HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 60: 768-772.
43. Tapia C, Schraml P, Simon R, Al-Kuraya KS, Maurer R, et al. (2004) HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. Int J Oncol 25: 1551-1557.
44. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, et al. (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616.
45. Hu Z, Fan C, Livasy C, He X, Oh DS, et al. (2009) A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med 7: 9.
46. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
47. Zhong H, SuYang H, Erdjument-Bromage H, Tempst P, Ghosh S, (1997) The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 89: 413-424.
48. Teo H, Ghosh S, Luesch H, Ghosh A, Wong ET, et al. (2010) Telomere-independent Rap1 is an IKK adaptor and regulates NF-kappaB-dependent gene expression. Nat Cell Biol 12: 758-767.
49. Sakurai H, Suzuki S, Kawasaki N, Nakano H, Okazaki T, et al. (2003) Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem 278: 36916-36923.
50. Buss H, Dörrie A, Schmitz ML, Hoffmann E, Resch K, et al. (2004) Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. J Biol Chem 279: 55633-55643.
51. Nihira K, Ando Y, Yamaguchi T, Kagami Y, Miki Y, et al. (2010) Pim-1 controls NF-kappaB signalling by stabilizing RelA/p65. Cell Death Differ 17: 689-698.
52. Walser TC, Rifat S, Ma X, Kundu N, Ward C, et al. (2006) Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 66: 7701-7707.
53. Soria G, Ben-Baruch A, (2008) The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267: 271-285.
54. Howe LR, (2007) Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 9: 210.
55. Grivennikov SI, Karin M, (2011) Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 70: i104-108.
56. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.